This is a working overview of Reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-11-23 and is reviewed periodically as new material appears.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Chain length | 29 amino acids | Based on the GRF(1-29) fragment |
| Appearance | White to off-white lyophilized powder | Common research supply form |
| Solubility | Soluble in water and aqueous buffers | Powder requires reconstitution before use |
| Typical storage | −20 °C or below | Kept away from light and moisture |
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
== Heterogeneous ribosomes == In 1958, Francis Crick famously proposed the "one gene-one ribosome-one protein hypothesis," where each ribosome carries the genetic information required to encode a single protein. Although discredited at that time, from the discovery of the first ribosomopathy Diamond–Blackfan Anemia in 1999, the ribosome has transitioned from a passive molecular machine to a dynamic macromolecular machine.Ribosomes are compositionally heterogeneous between species and even within the same cell, as evidenced by the existence of cytoplasmic and mitochondria ribosomes within the same eukaryotic cells. Certain researchers have suggested that heterogeneity in the composition of ribosomal proteins in mammals is important for gene regulation, i.e., the specialized ribosome hypothesis. However, this hypothesis is controversial and the topic of ongoing research. Heterogeneity in ribosome composition was first proposed to be involved in translational control of protein synthesis by Vince Mauro and Gerald Edelman. They proposed the ribosome filter hypothesis to explain the regulatory functions of ribosomes. Evidence has suggested that specialized ribosomes specific to different cell populations may affect how genes are translated. Some ribosomal proteins exchange from the assembled complex with cytosolic copies suggesting that the structure of the in vivo ribosome can be modified without synthesizing an entire new ribosome. Certain ribosomal proteins are absolutely critical for cellular life while others are not.
Historically, slaves in the Arab World came from many different regions, including Sub-Saharan Africa (mainly Zanj), the Caucasus (mainly Circassians), Central Asia (mainly Tartars), and Central and Eastern Europe (mainly Slavs Saqaliba). These slaves were trafficked to the Arab world from Africa via the Trans-Saharan slave trade, the Baqt treaty, the Red Sea slave trade and the Indian Ocean slave trade; from Asia via the Bukhara slave trade; and from Europe via the Prague slave trade, the Venetian slave trade and the Barbary slave trade, respectively.
== Cultivation == The plants are propagated by cuttings about 40 to 50 cm (16 to 20 in) long, usually cultivars selected both for yield and quality of fruit. These are tied up to neighbouring trees or climbing frames at distances of about 2 m (6+1⁄2 ft) apart; trees with rough bark are favoured over those with smooth bark, as the pepper plants climb rough bark more readily. Competing plants are cleared away, leaving only sufficient trees to provide shade and permit free ventilation. The roots are covered in leaf mulch and manure, and the shoots are trimmed twice a year. On dry soils, the young plants require watering every other day during the dry season for the first three years. The plants bear fruit from the fourth or fifth year, and then typically for seven years. Harvesting begins as soon as one or two fruits at the base of the spikes begin to turn red, and before the fruit is fully mature, and still hard; if allowed to ripen completely, the fruits lose pungency, and ultimately fall off and are lost. The spikes are collected and spread out to dry in the sun, then the peppercorns are stripped off the spikes.
Sources: en.wikipedia.org
For dinosterol derivatives, analysis is typically carried out by capillary gas chromatography and capillary gas chromatography-mass spectrometry. The mass spectrum of dinosterol as the TMS-ether shows characteristic ions at m/z 500 (M+), 429, 388, 359, 339 and 271. The base peak at m/z 69 is diagnostic for the A:2-unsaturated 23,24-dimethyl sidechain. Other purification techniques for dinosterol include various combinations of thin layer (TLC) and column chromatography with a variety of phases, AgNO3 impregnated Silica gel chromatography, normal phase-high performance liquid chromatography (NP-HPLC), and reversed phase-high performance liquid chromatography (RP-HPL).An alternative method has been proposed for purifying dinosterol from complex mixtures of sedimentary lipids for the purpose of hydrogen isotope analysis via gas chromatography-isotope ratio mass spectrometry (GC-IRMS). Reversed phase-high performance liquid chromatography (RP-HPLC) is used to separate dinosterol from structurally similar 4α-methyl sterols that co-elute on GC analysis, which allows for baseline resolution of dinosterol. For samples that contain a variety of 4a-methyl sterols, RP-HPLC purification can be preceded by NP-HPLC purification.
For services to Education. Donna Jones. Team Leader, Ministry of Defence. For services to Defence. Janet Elizabeth Kay. Kinship Carer, Kinship. For services to Children and Families. Professor Simon Edward Kenny. National Clinical Director for Children and Young People, NHS England and Consultant Paediatric Surgeon, Alder Hey Children's Hospital. For services to Paediatric Surgery. Professor Bienvenido Arturo Langa Ferreira. Consultant Psychiatrist, NHS Lanarkshire. For services to Vulnerable People in Scotland. Nicholas David Leader. Lately Governor, HM Prison Berwyn. For Public Service. Kathryn Maria Leahy. Director of Operations, Heathrow Airport. For services to Aviation Transport and to Major Events. Cathryn Lee. Chief Executive, Alzheimer's Society. For services to Charity. Janet Legrand, KC. Lately Chair of Trustees, The Children's Society. For services to Young People. Carl Anthony Les. Leader, North Yorkshire Council. For services to Local Government. Philip John Loach, QFSM. Lately Chief Fire Officer, West Midlands Fire and Rescue Service. For services to Fire and Rescue. Dr. William Patrick James Lockhart. Deputy Director, International Biodiversity and Wildlife, Department for Environment, Food and Rural Affairs. For services to the Environment. Antony Craig Lockley. Director of Strategy and Assistant Chief Executive, Blackpool Council. For services to Local Government. Professor Mark Logan, FRSE. Chief Entrepreneurial Adviser to the Scottish Government. For services to the Economy. Sally-Ann Loudon.
Few labs are subject to complaints. For 2024, CLIA budgeted for approximately 209 onsite complaint surveys, representing ~0.06% of the 320,000 CLIA labs. The low volume of lab complaints may be related to complainants' concerns about anonymity and fear of retaliation for filing a complaint. It may be easy for a lab to determine the source of a complaint filed by a lab worker. For example, in some cases, either the nature of the complaint or the piece of testing equipment in question could narrow the list of possible complainants. Because of the difficulty of protecting the anonymity of lab workers who file complaints, whistle-blower protections for such individuals are particularly important. Following congressional testimony by a Maryland hospital lab worker that she and her colleagues feared losing their jobs because of the complaints, a whistleblower protection bill, the "Clinical Laboratory Compliance Improvement Act of 2005", was introduced, but died in committee. CLIA and federal law provide no specific whistleblower protection to laboratory employees who report CLIA violations. However, CLIA complaints made under the False Claims Act (FCA) may be afforded whistleblower protections. The FCA, which prohibits fraud against government programs, including Medicare and Medicaid, may cover CLIA violations that give rise to FCA violations, such as laboratory deficiencies that render billed services medically worthless. Whether CLIA compliance is a condition of Medicare payment is a contested issue.
Other appropriate antihypertensive drugs to administer during hypertensive crisis resulting from stimulant overdose are vasodilators such as nitroglycerin, diuretics such as furosemide, and alpha blockers such as phentolamine. Beta blockers were found to be associated with depression in earlier studies. More lipophilic beta blockers, with greater central effects, were especially implicated. However, subsequent more rigorous studies found no causal relationship of beta blockers with depression and regardless of lipid solubility. A small and significant but inconsistent risk of fatigue was found for non-selective beta blockers however. Beta blockers, due to their antagonism at β1 adrenergic receptors, inhibit both the synthesis of new melatonin and its secretion by the pineal gland. More lipophilic beta blockers, with greater ability to cross the blood–brain barrier, are known to be able to suppress melatonin release by 50 to 80%. The neuropsychiatric side effects of some beta blockers (e.g. sleep disruption, insomnia) may be related to this effect.
Sources: en.wikipedia.org
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.
DAC stands for drug affinity complex, a chemical group that binds the peptide to serum albumin. The binding slows clearance and lengthens the time the molecule stays in plasma compared with the unmodified analog.
Because two distinct molecules are discussed under one informal label. The albumin-binding version clears over several days, while the form without that group clears within roughly half an hour. Mixing results from both creates inconsistent figures.
Natural GHRH is degraded quickly by dipeptidyl peptidase-4 and related enzymes, giving it a half-life measured in minutes. CJC-1295 carries substitutions that slow that breakdown, so it stays intact longer. Both act at the same pituitary receptor and produce the same class of signal.